Skip to content
value.today

LigoCyte Pharmaceuticals Inc

🇺🇸 Bozeman, Montana, USAPharmaceuticalsFounded 2008
Total raised
$44 M
4 rounds on record
Latest round
$2 M
Jun 2012
First round on record
Mar 2008
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of LigoCyte Pharmaceuticals Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2012$2 MNo. 4$2 to $10 million

LigoCyte Pharmaceuticals Inc: Raise no. 4, Jun 2012

Investors in this round

7 investors had bought by the notice of Jun 28, 2012: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $22 M offered; $20 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • C. Boyd Clarke · Executive Officer, Director
  • Donald Beeman · Executive Officer, Director
  • Larry Mikkola · Executive Officer
  • Robert Goodwin · Executive Officer
  • Ben Auspitz · Director
  • Hironori Boyd Hozoji · Director
  • Ivor Royston · Director
  • J. Donald deBethizy · Director
  • Markus Boyd Goebel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Donald Beeman, Ceo. Source: SEC Form D, newest notice filed Jun 28, 2012. Read the notice at the SEC.

equity, debt, optionsSEC
Jun 2011$6 MNo. 3$2 to $10 million

LigoCyte Pharmaceuticals Inc: Raise no. 3, Jun 2011

Investors in this round

11 investors had bought by the notice of Jun 21, 2011: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $13 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Donald Beeman · Executive Officer, Director
  • Larry Mikkola · Executive Officer
  • Robert Goodwin · Executive Officer
  • Ben Auspitz · Director
  • C. Boyd Clarke · Director
  • George Boyd Kemble · Director
  • Hironori Boyd Hozoji · Director
  • Ivor Royston · Director
  • J. Donald deBethizy · Director
  • Markus Boyd Goebel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Donald Beeman, Ceo. Source: SEC Form D, newest notice filed Jun 21, 2011. Read the notice at the SEC.

debt, optionsSEC
Apr 2010$7 MNo. 2$2 to $10 million

LigoCyte Pharmaceuticals Inc: Raise no. 2, Apr 2010

Investors in this round

15 investors had bought by the notice of May 28, 2010: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $15 M offered; $8 M still to sell
Smallest investment taken
$5,000
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Donald Beeman · Executive Officer, Director
  • Larry Mikkola · Executive Officer
  • Robert Goodwin · Executive Officer
  • Ben Auspitz · Director
  • C. Boyd Clarke · Director
  • George Boyd Kemble · Director
  • Hironori Boyd Hozoji · Director
  • Ivor Royston · Director
  • J. Donald deBethizy · Director
  • Markus Boyd Goebel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Robert Goodwin, President. Source: SEC Form D and 1 amendment, newest notice filed May 28, 2010. Read the notice at the SEC.

debt, optionsSEC
Mar 2008$29 MNo. 1$10 to $50 million

LigoCyte Pharmaceuticals Inc: Raise no. 1, Mar 2008

Investors in this round

23 investors had bought by the notice of Aug 14, 2009: 23 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$29 M of $29 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: includes two warrants to purchase Series C Preferred Stock
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$1,590,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Donald P. Beeman · Executive Officer, Director
  • Larry Mikkola · Executive Officer
  • Rob Goodwin · Executive Officer
  • Ben Auspitz · Director
  • C. Boyd Clarke · Director
  • George Kemble, Ph.D. · Director
  • Hironori Hozoji · Director
  • Ivor Royston, M.D. · Director
  • J. Donald deBethizy, Ph.D. · Director
  • Markus Goebel, M.D., Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Seaview Securities LLC (CRD 126180) · broker-dealer Seaview Securities LLC (CRD 126180) · New York, NySold in no state named

Signed by Donald P. Beeman, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 14, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • LigoCyte Pharmaceuticals Inc chose not to state its revenue in its newest notice of a funding round (Jun 2012).

    SEC Form D · Jun 2012

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jun 2012

That is all the official record says: LigoCyte Pharmaceuticals Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of LigoCyte Pharmaceuticals Inc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 23 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by LigoCyte Pharmaceuticals Inc
NameRoleNamed in
C. Boyd ClarkeExecutive officerJun 2012
Donald BeemanExecutive officerJun 2012
Larry MikkolaExecutive officerJun 2012
Robert GoodwinExecutive officerJun 2012
Donald P. BeemanExecutive officerAug 2009
Rob GoodwinExecutive officerAug 2009
Ben AuspitzDirectorJun 2012
C. Boyd ClarkeDirectorJun 2012
Donald BeemanDirectorJun 2012
Hironori Boyd HozojiDirectorJun 2012
Ivor RoystonDirectorJun 2012
J. Donald deBethizyDirectorJun 2012
Markus Boyd GoebelDirectorJun 2012
George Boyd KembleDirectorJun 2011
Donald P. BeemanDirectorAug 2009
George Kemble, Ph.D.DirectorAug 2009
Hironori HozojiDirectorAug 2009
Ivor Royston, M.D.DirectorAug 2009
J. Donald deBethizy, Ph.D.DirectorAug 2009
Markus Goebel, M.D., Ph.D.DirectorAug 2009